M1 CRPC: PARP Inhibitors and Precision Medicine

M1 CRPC: PARP Inhibitors, Microsatellite Instability  and Precision MedicineПодробнее

The Role of PARP Inhibitors in Advanced Prostate CancerПодробнее

Prostate cancer updates: Advances in precision medicine and PARP inhibitorsПодробнее

M1 - PARP inhibitors as monotherapy in advanced prostate cancerПодробнее

Precision Medicine in mCRPCПодробнее

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid TumorsПодробнее

Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel ChemotherapyПодробнее

M1 CRPC: Treatment Sequencing and Future DirectionsПодробнее

The Landscape of Radiopharmaceuticals and PARP Inhibitors in CRPCПодробнее

PARPi: Precision Medicine in Advanced Prostate CancerПодробнее

PARP Inhibitors for Prostate Cancer with Moshe Ornstein, MDПодробнее

Choosing the correct PARP inhibitor for prostate cancerПодробнее

Identifying Mutations and Optimizing Use of PARP InhibitorsПодробнее

PARP Inhibitors: Assessing the Clinical Trial LandscapeПодробнее

Castration Resistant Prostate Cancer: Diagnosis & Testing Considerations With Use of PARP InhibitorsПодробнее

Round-table discussion on PARP inhibitorПодробнее

PARP Inhibitors: Assessing the Clinical Trial LandscapeПодробнее

PARP Inhibitors in Advanced Prostate Cancer CareПодробнее

PARPi: Precision Medicine in Advanced Prostate Cancer (2023)Подробнее